Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DNMT3A | Q9Y6K1 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.43 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11943242 | 0.81 | DCTPP1 (0.53) | ALDH1A1SMN1; SMN2DNMT3ASIGMAR1DCTPP1 | |
| SCHEMBL11943238 | 0.81 | TP53 (0.42) | ALDH1A1SMN1; SMN2DCTPP1TP53RXFP1 | |
| SCHEMBL11943261 | 0.78 | DCTPP1 (0.47) | ALDH1A1SMN1; SMN2DNMT3ASIGMAR1DCTPP1 | |
| SCHEMBL11943160 | 0.76 | FAAH (0.56) | ALDH1A1SMN1; SMN2DCTPP1KMT2ARXFP1 | |
| SCHEMBL13329125 | 0.74 | FAAH (0.48) | SMN1; SMN2DCTPP1TP53KDM4E | |
| SCHEMBL11943270 | 0.73 | MAPT (0.48) | SMN1; SMN2DCTPP1TP53KDM4EKMT2A | |
| SCHEMBL11943310 | 0.73 | ALDH1A1 (0.48) | ALDH1A1DNMT3ADCTPP1KMT2A | |
| SCHEMBL11943268 | 0.73 | DCTPP1 (0.42) | ALDH1A1SMN1; SMN2DCTPP1RXFP1 | |
| SCHEMBL11943275 | 0.73 | FAAH (0.52) | ALDH1A1SIGMAR1KDM4EKMT2A | |
| SCHEMBL11943154 | 0.73 | GLA (0.49) | ALDH1A1SMN1; SMN2DCTPP1KDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | DPM1, GMPS, MAN2A1 | ALDH1A1 2003/4885SMN1; SMN2 3332/4885DNMT3A 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.